Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Austria, Vienna, 2 September 2007:
There are major differences in the risk profile and characteristics of female patients treated for acute heart failure. Female patients are underrepresented in management trials on Heart Failure. According to data from the Euro Heart Survey on acute Heart Failure 2004-2005 in Europe, however, medical treatment has improved.
Female patients ( m 75 years) are on average 6 years older than male subjects. They represent about 40 – 50% of all acute heart failure hospitalizations. Smoking as risk factor is present only in 15.7% of females compared to 60% in male subjects. Therefore COPD was reported in only 15% of females versus 22% of male subjects. Furthermore the females have less coronary artery disease than males -- 43% compare to 69% in males -- but more hypertension and valvular disease than males. Anemia and thyroid diseases are more prevalent, while renal problems, probably related to atherosclerosis, are more prevalent in male subjects.
Acute coronary syndrome is equally prevalent as precipitating factor in 31% of acute heart failure. Valvular heart disease, arrythmias and especially atrial fibrillation are more prevalent precipitating factors in females. These background characteristics affect medical treatment.
It is noteworthy that less angiography is performed in females (31 % compared to 40%). Similarly, invasive therapies including other catheterizations, balloon pumping and coronary interventions were less frequent. The difference in interventions may be related to age and clinical picture.
Aldosterone antagonists, antiarrhythmic drugs, aspirin and lipid lowering drugs were less frequently prescribed to women, whereas they more often received calcium channel blockers, digoxin and insulin at admission. However, after adjustment for clinically significant covariates (age, history CHD and CHF, known systolic dysfunction and atrial fibrillation) there were no statistically significant differences in prescribing cardiovascular medication to women as compared with men. The prescription rate of all cardiovascular medications increased from admission to discharge with the exception of calcium channel blockers which were prescribed less often at discharge.
The female patients in younger or older age groups have better prognosis than male subjects.
The medical management of European females is well justified and no major gender differences can be detected. There are less invasive procedures performed for females probably due to background risk factors and illnesses. Prognosis is better in female than in male subjects.
This study was presented at the ESC Congress 2007 in Vienna.
© 2017 European Society of Cardiology. All rights reserved